EP1100878B8 - Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells - Google Patents

Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells Download PDF

Info

Publication number
EP1100878B8
EP1100878B8 EP99948706A EP99948706A EP1100878B8 EP 1100878 B8 EP1100878 B8 EP 1100878B8 EP 99948706 A EP99948706 A EP 99948706A EP 99948706 A EP99948706 A EP 99948706A EP 1100878 B8 EP1100878 B8 EP 1100878B8
Authority
EP
European Patent Office
Prior art keywords
stem cells
genetically modified
negative
therapy
adherently growing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99948706A
Other languages
German (de)
French (fr)
Other versions
EP1100878A2 (en
EP1100878B1 (en
Inventor
Ralf Huss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1100878A2 publication Critical patent/EP1100878A2/en
Application granted granted Critical
Publication of EP1100878B1 publication Critical patent/EP1100878B1/en
Publication of EP1100878B8 publication Critical patent/EP1100878B8/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of genetically modified, very early haematopoietic and mesenchymal stem cells (negative for the expression of the surface molecule CD34) in the individual gene therapy of mono- or oligogenetic diseases or in cell therapy. Autologous CD34-negative adherently growing stem cell cultures from the peripheral blood of the patient are applied and efficiently tranfected or infected with genetic constructs. The gene products of these genes should substitute defective or absent proteins or factors in the patient organism in the long term. After expansion, the autologous stem cells can also be used for cell therapy (organ replacement therapy).
EP99948706A 1998-07-24 1999-07-22 Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells Expired - Lifetime EP1100878B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19833476A DE19833476B4 (en) 1998-07-24 1998-07-24 Genetically modified CD34 negatives, adherently growing hematopoietic stem cells and their use in gene therapy
DE19833476 1998-07-24
PCT/DE1999/002309 WO2000006705A2 (en) 1998-07-24 1999-07-22 Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy

Publications (3)

Publication Number Publication Date
EP1100878A2 EP1100878A2 (en) 2001-05-23
EP1100878B1 EP1100878B1 (en) 2005-06-01
EP1100878B8 true EP1100878B8 (en) 2005-08-17

Family

ID=7875274

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99948706A Expired - Lifetime EP1100878B8 (en) 1998-07-24 1999-07-22 Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells

Country Status (9)

Country Link
US (1) US6361997B1 (en)
EP (1) EP1100878B8 (en)
JP (1) JP4012688B2 (en)
AT (1) ATE296875T1 (en)
AU (1) AU741168B2 (en)
CA (1) CA2338541C (en)
DE (2) DE19833476B4 (en)
ES (1) ES2242422T3 (en)
WO (1) WO2000006705A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147722A0 (en) * 1999-07-20 2002-08-14 Univ Southern California Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US20020045260A1 (en) * 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
JP2004529621A (en) * 2001-02-14 2004-09-30 ティー ファークト，レオ Pluripotent adult stem cells, their origin, methods of obtaining and maintaining them, methods of differentiating them, methods of their use, and cells derived therefrom
US20070111201A1 (en) * 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
DE10144326B4 (en) * 2001-09-10 2005-09-22 Siemens Ag Method and system for monitoring a tire air pressure
ITRM20030376A1 (en) 2003-07-31 2005-02-01 Univ Roma PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP2087098A4 (en) * 2006-11-09 2010-03-31 Univ Johns Hopkins Dedifferentiation of adult mammalian cardiomyocytes into cardiac stem cells
WO2008063675A2 (en) * 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
WO2008150368A1 (en) * 2007-05-24 2008-12-11 Apceth Gmbh & Co. Kg Cd34 stem cell-related methods and compositions
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
JP6433896B2 (en) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Exosomes and microribonucleic acids for tissue regeneration
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
JP6878274B2 (en) 2014-10-03 2021-05-26 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Myocardial cell-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
CA3059634A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3612191A4 (en) 2017-04-19 2020-12-30 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744347A (en) * 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5921856A (en) 1997-07-10 1999-07-13 Sp3, Inc. CVD diamond coated substrate for polishing pad conditioning head and method for making same

Also Published As

Publication number Publication date
ES2242422T3 (en) 2005-11-01
DE19833476A1 (en) 2000-01-27
WO2000006705A2 (en) 2000-02-10
ATE296875T1 (en) 2005-06-15
US6361997B1 (en) 2002-03-26
EP1100878A2 (en) 2001-05-23
JP2003527817A (en) 2003-09-24
WO2000006705A3 (en) 2000-05-04
DE59912118D1 (en) 2005-07-07
JP4012688B2 (en) 2007-11-21
CA2338541C (en) 2007-04-03
EP1100878B1 (en) 2005-06-01
AU741168B2 (en) 2001-11-22
AU6187299A (en) 2000-02-21
CA2338541A1 (en) 2000-02-10
DE19833476B4 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
EP1100878B8 (en) Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells
Zhu et al. Periodontal ligament stem cells: current status, concerns, and future prospects
CN102282252B (en) Amnion-derived attached cell
Suchánek et al. Human dental pulp stem cells-isolation and long term cultivation
Terai et al. Immortalization of human fetal cells: the life span of umbilical cord blood-derived cells can be prolonged without manipulating p16INK4a/RB braking pathway
Yang et al. Regulation of the secretion of immunoregulatory factors of mesenchymal stem cells (MSCs) by collagen-based scaffolds during chondrogenesis
AU4336499A (en) Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
Dai et al. Non-genetic direct reprogramming and biomimetic platforms in a preliminary study for adipose-derived stem cells into corneal endothelia-like cells
HUP0500477A2 (en) Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
JPH1189587A (en) Genetically modified cell and its use in preventing and treating disease
Narang et al. Stem cells: A potential regenerative future in dentistry
Pantic et al. Reliable and versatile immortal muscle cell models from healthy and myotonic dystrophy type 1 primary human myoblasts
CN110305839A (en) Mesenchymal stem cell serum-free culture medium
Olmedo-Moreno et al. Heterogeneity of in vitro expanded mesenchymal stromal cells and strategies to improve their therapeutic actions
KR20170036105A (en) Stem cell compositions and methods of producing stem cells for therapeutic applications
Silini et al. CM from intact hAM: an easily obtained product with relevant implications for translation in regenerative medicine
KR920004570A (en) Gene encoding human MK protein, expression vector and host cell comprising same, method for producing and using MK protein
ATE400654T1 (en) NEW MAMMAL GENE BC1-W, WHICH BELONGS TO THE BC1-2 FAMILY OF APOPTOSIS-CONTROLING GENES
Saini et al. Therapeutics of stem cells in periodontal regeneration
Murakami et al. Isolation and characterization of lymphoid enhancer factor-1-positive deciduous dental pulp stem-like cells after transfection with a piggyBac vector containing LEF1 promoter-driven selection markers
DE50009932D1 (en) Gene transfer into human lymphocytes using retroviral SCFV cell culture vectors
CN1536076A (en) Method for making adult bone marrow mesenchymal stem cells implement in vito amplification and directionally inducing them to be differentiated into myocardium-like cells
Zhou et al. Treating congenital megacolon by transplanting GDNF and GFRα-1 double genetically modified rat bone marrow mesenchymal stem cells
Radfar et al. Transplantation of virally transduced cells into the dermis of immunocompetent and immunodeficient (SCID) mice to determine gene expression profile and differential donor cell survival
Zhu et al. Differentiation of Human umbilical cord-derived mesenchymal stem cells to melanocyte, Osteogenic and Neural cells in vitro

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20011019

RTI1 Title (correction)

Free format text: GENETICALLY MODIFIED CD34-NEGATIVE ADHERENTLY GROWING HAEMATOPOIETIC STEM CELLS AND THEIR USE IN GENE THERAPY

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: PROCESS FOR PRODUCING GENETICALLY MODIFIED CD34-NEGATIVE ADHERENTLY GROWING HAEMATOPOIETIC STEM CELLS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050601

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050601

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050601

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REF Corresponds to:

Ref document number: 59912118

Country of ref document: DE

Date of ref document: 20050707

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050722

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050731

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050901

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050901

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050901

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20050922

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2242422

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051103

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

ET Fr: translation filed
26N No opposition filed

Effective date: 20060302

BERE Be: lapsed

Owner name: HUSS, RALF

Effective date: 20050731

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: HUSS, RALF

Free format text: HUSS, RALF#TEGERNSEER STRASSE 78#83666 WAAKIRCHEN (DE) -TRANSFER TO- HUSS, RALF#TEGERNSEER STRASSE 78#83666 WAAKIRCHEN (DE)

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: APCETH GMBH & CO. KG

Free format text: HUSS, RALF#TEGERNSEER STRASSE 78#83666 WAAKIRCHEN (DE) -TRANSFER TO- APCETH GMBH & CO. KG#ROSENHEIMER PLATZ 6#81669 MUENCHEN (DE)

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20090514 AND 20090520

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20140620

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20140725

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20150723

Year of fee payment: 17

Ref country code: DE

Payment date: 20150729

Year of fee payment: 17

Ref country code: GB

Payment date: 20150724

Year of fee payment: 17

Ref country code: ES

Payment date: 20150723

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 59912118

Country of ref document: DE

Representative=s name: HERTIN & PARTNER RECHTS- UND PATENTANWAELTE PA, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 59912118

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150730

Year of fee payment: 17

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 296875

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150722

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 59912118

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160731

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170201

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160722

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180507

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160723